KR960010008A - 수성 경비 현탁액 - Google Patents

수성 경비 현탁액 Download PDF

Info

Publication number
KR960010008A
KR960010008A KR1019950032015A KR19950032015A KR960010008A KR 960010008 A KR960010008 A KR 960010008A KR 1019950032015 A KR1019950032015 A KR 1019950032015A KR 19950032015 A KR19950032015 A KR 19950032015A KR 960010008 A KR960010008 A KR 960010008A
Authority
KR
South Korea
Prior art keywords
drug
cyclodextrin
aqueous nasal
nasal suspension
suspension according
Prior art date
Application number
KR1019950032015A
Other languages
English (en)
Inventor
마사코 기무라
야스시 모리타
구니히로 후쿠니
Original Assignee
요시다 쇼지
센주 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 요시다 쇼지, 센주 세이야쿠 가부시키가이샤 filed Critical 요시다 쇼지
Publication of KR960010008A publication Critical patent/KR960010008A/ko

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 a) 시클로텍스트린 및 b) 1 기압하의 25℃에서 균일한 혼합물이 수득되도록 약물 1중량부에 대해 1000중량부 이상의 물을 지니며, 용해도법에 의해 계산시 시클로덱스트린과 관련한 안정도 상수가 1000 이하인 거의 용해되지 않는 약물을 함유하는 수성 경비 현탁액에 관한 것이다. 본 발명의 수성 경비 현탁액은 물에 거의 용해되지 않는 약물의 약리학적 효능을 증가시키고 비점막내의 약물의 저류성을 개선하며 약물작용을 지속시켜서, 투여 빈도를 감소시킬 수 있다. 그러므로 이 경비 현탁액은 개선된 환자 복용성을 확보하기 위해 가치 있는 국소 경비 제제로서 사용될 수 있다.

Description

수성 경비 현탁액
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 다음의 a) 및 b)성분을 함유하는 수성 경비 현탁액 : a) 시클로덱스트린 b) 1 기압하의 25℃에서 균일한 혼합물이 수득되도록 약물 1중량부에 대해 1000중량부 이상의 물을 지니며, 용해도법에 의해 계산시 시클로덱스트린과 관련한 안정도 상수가 1000 이하인 거의 용해되지 않는 약물
  2. 제1항에 있어서, 상기 용해도가 낮은 약물이 국소용인 수성 경비 현탁액
  3. 제1항에 있어서, 상기 용해도가 낮은 약물이 스테로이드 항염증제, 비스테로이드 항염증제, 항히스타민제, 항미생물제 및 항알레르기제로 이루어진 군으로부터 선택되는 하나 이상의 화학종인 수성 경비 현탁액
  4. 제3항에 있어서, 상기 용해도가 낮은 약물이, 상기 스테로이드 항염증제로서는 로테프레드놀에타보네이트, 플루오로메톨론, 베클로메타손, 디프로피오네이트 및 플루티카손 프로피오네이트, 상기 비스테로이드 항염증제로서는 메페남산, 상기 항히스타민제로서는 클레마스틴 푸마레이트 및 테르페나딘, 항알레르기제로서는 트라닐라스트 중에서 선택되는 하나 이상이 화학중인 수성 경비 현탁액
  5. 제4항에 있어서, 상기 스테로이드 항염증제가 로테프레드놀 에타보네이트인 수성 경비 현탁액
  6. 제1항에 있어서, 시클로덱스트린이 1.0-10.0(w/v)%의 농도로 함유된 수성 경비 현탁액
  7. 제1항에 있어서, 상기 시클로덱스티린이 α-시클로덱스트린인 수성 경비 현탁액
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950032015A 1994-09-28 1995-09-27 수성 경비 현탁액 KR960010008A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP94-233267 1994-09-28
JP23326794 1994-09-28

Publications (1)

Publication Number Publication Date
KR960010008A true KR960010008A (ko) 1996-04-20

Family

ID=16952416

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950032015A KR960010008A (ko) 1994-09-28 1995-09-27 수성 경비 현탁액

Country Status (4)

Country Link
EP (1) EP0709099A3 (ko)
KR (1) KR960010008A (ko)
AU (1) AU3290595A (ko)
CA (1) CA2159288A1 (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974350B1 (en) 1996-02-07 2002-08-28 Lead Chemical Company Ltd. External preparation containing tranilast and process for producing the same
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
KR100508227B1 (ko) * 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
DE69837664T2 (de) 1997-05-14 2008-01-03 Senju Pharmaceutical Co., Ltd. Wässrige suspensionspräparationen mit exzellenter redispersibilität
DE19839515B4 (de) * 1998-08-29 2012-02-02 Nanohale Gmbh Neue pharmazeutische Zubereitung, enthaltend kolloidale Polymer-Wirkstoff-Assoziate, insbesondere auch für mucosale Wirkstoffverabreichung
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
DE19947234A1 (de) 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
US20020132803A1 (en) * 2001-01-05 2002-09-19 Mahendra Dedhiya Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus
US7029657B2 (en) 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
US6958142B2 (en) 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US6960337B2 (en) 2002-08-02 2005-11-01 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders
PL373433A1 (en) 2002-08-30 2005-08-22 Altana Pharma Ag The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
WO2004082589A2 (en) * 2003-03-20 2004-09-30 Ranbaxy Laboratories Limited Nasally administrable, bioavailable pharmaceutical composition of loratadine
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
JP2006008568A (ja) * 2004-06-24 2006-01-12 Cyclochem:Kk ＩｇＥ抗体抑制剤および食品
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US9023793B2 (en) * 2006-09-29 2015-05-05 Retrophin, Inc. Intranasal carbetocin formulations and methods for the treatment of autism

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5835772A (ja) 1981-08-23 1983-03-02 Sony Corp 回転駆動台
JPS58189118A (ja) 1982-04-30 1983-11-04 Takeda Chem Ind Ltd 経鼻投与製剤
NZ225045A (en) 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
EP0381747A4 (en) 1988-08-15 1991-09-11 American Maize-Products Company Water soluble branched beta cyclodextrin steroid complex
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
JP2805539B2 (ja) 1990-09-20 1998-09-30 参天製薬株式会社 ポリ―γ―シクロデキストリン包接化合物
JP3176716B2 (ja) 1991-06-21 2001-06-18 武田薬品工業株式会社 溶解性が向上した難水溶性薬物組成物
JPH0570612A (ja) 1991-09-12 1993-03-23 Toyobo Co Ltd 二軸配向ポリエステルフイルム

Also Published As

Publication number Publication date
CA2159288A1 (en) 1996-03-29
EP0709099A2 (en) 1996-05-01
AU3290595A (en) 1996-04-18
EP0709099A3 (en) 1996-07-24

Similar Documents

Publication Publication Date Title
KR960010008A (ko) 수성 경비 현탁액
KR870010862A (ko) 비내투여용 수성 스테로이드 제제
US5955454A (en) Nasal pharmaceutical composition containing a progestogen
EP1562621B1 (en) Composition for treating ichthyosis using antitrypsin
EP0998916B1 (en) Medicinal compositions for application to mucosa
US4775529A (en) Steroid lotion
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
JO1250B1 (en) New pharmaceutical preparations
PT1079806E (pt) Preparacoes para a aplicacao de anti-inflamatorios, especialmente, agentes anti-septicos e/ou agentes de promocao da cura de feridas, no tracto respiratorio superior e/ou no ouvido
KR970704452A (ko) 앨러지성 안질환을 치료하기 위한 독세핀 유도체를 함유하는 국소적 안과용 제제(Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases)
US6780398B1 (en) Aqueous nasal formulation
ATE343374T1 (de) Fluticasonpropionat arzneizubereitung
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
EA200201059A1 (ru) Препараты, содержащие глюкокортикостероидное лекарственное средство, для лечения бронхолегочных заболеваний
KR930019224A (ko) 유산 위험 치료제
ATE241959T1 (de) Formulierungen von steroidlösungen zur inhalativen verabreichung
KR900701278A (ko) 바이러스 감염 치료용 담즙산
EP0162239A1 (en) Percutaneous absorption accelerator and preparation containing same
KR920703060A (ko) 제약학적 배합물
KR910004186A (ko) 제약학적 배합물
US5721228A (en) Rectal flunisolide compositions for treating inflammatory intestinal disorders
KR950032229A (ko) 코르티코이드 유도체와 약학적 및 화장품용 조성물
KR960021028A (ko) 항염증성 스테로이드(steroid) 구내염 치료제
WO2001003774A3 (en) Pharmaceutical composition for the treatment of calcification
JPH069430A (ja) 安定なリゾチーム配合点眼剤

Legal Events

Date Code Title Description
WITN Withdrawal due to no request for examination